Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage
biopharmaceutical company dedicated to the research, development
and commercialization of innovative therapies for rare diseases of
the eye, today announced that it will present at the H.C.
Wainwright 24th Annual Global Investment Conference, being held
virtually and in New York, NY. A pre-recorded fireside chat will be
made available beginning Monday, September 12, 2022 at 7:00 a.m.
ET. Management will also be available for one-on-one meetings
throughout the conference.
To access the webcast and subsequent archived recording of the
fireside chat, please visit the “Presentations” section of the Kala
website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a clinical-stage biopharmaceutical company dedicated to
the research, development and commercialization of innovative
therapies for rare diseases of the eye. Kala’s biologics-based
investigational therapies utilize Kala’s proprietary Mesenchymal
Stem Cell Secretome (MSC-S) platform. Kala’s lead product
candidate, KPI-012, is in clinical development for the treatment of
persistent corneal epithelial defect (PCED), a rare disease of
impaired corneal healing, which has received orphan drug
designation from the U.S. Food and Drug Administration. Kala is
also targeting the potential development of KPI-012 for the
treatment of Partial Limbal Stem Cell Deficiency and ocular
manifestations of moderate-to-severe Sjögren's and plans to
initiate preclinical studies to evaluate the utility of its MSC-S
platform for retinal degenerative diseases, such as Retinitis
Pigmentosa and Stargardt Disease. For more information on Kala,
please visit www.kalarx.com.
Investor Contact:
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024